Sangamo Therapeutics Inc (SGMO)
0.867
+0.02
(+2.66%)
USD |
NASDAQ |
Sep 27, 16:00
0.8433
-0.02
(-2.73%)
After-Hours: 20:00
Sangamo Therapeutics Research and Development Expense (TTM): 167.91M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 167.91M |
| March 31, 2024 | 206.73M |
| December 31, 2023 | 234.06M |
| September 30, 2023 | 249.53M |
| June 30, 2023 | 257.56M |
| March 31, 2023 | 254.53M |
| December 31, 2022 | 249.90M |
| September 30, 2022 | 235.52M |
| June 30, 2022 | 232.90M |
| March 31, 2022 | 232.97M |
| December 31, 2021 | 230.82M |
| September 30, 2021 | 231.38M |
| June 30, 2021 | 214.16M |
| March 31, 2021 | 195.60M |
| December 31, 2020 | 180.65M |
| September 30, 2020 | 166.62M |
| June 30, 2020 | 157.62M |
| March 31, 2020 | 152.55M |
| December 31, 2019 | 145.92M |
| September 30, 2019 | 140.85M |
| June 30, 2019 | 133.37M |
| March 31, 2019 | 126.17M |
| December 31, 2018 | 114.87M |
| September 30, 2018 | 100.99M |
| June 30, 2018 | 90.60M |
| Date | Value |
|---|---|
| March 31, 2018 | 76.33M |
| December 31, 2017 | 65.73M |
| September 30, 2017 | 60.24M |
| June 30, 2017 | 58.82M |
| March 31, 2017 | 63.29M |
| December 31, 2016 | 65.62M |
| September 30, 2016 | 71.63M |
| June 30, 2016 | 71.32M |
| March 31, 2016 | 67.48M |
| December 31, 2015 | 67.20M |
| September 30, 2015 | 62.38M |
| June 30, 2015 | 62.03M |
| March 31, 2015 | 59.87M |
| December 31, 2014 | 56.97M |
| September 30, 2014 | 52.72M |
| June 30, 2014 | 45.08M |
| March 31, 2014 | 40.90M |
| December 31, 2013 | 37.04M |
| September 30, 2013 | 35.48M |
| June 30, 2013 | 34.35M |
| March 31, 2013 | 32.65M |
| December 31, 2012 | 31.71M |
| September 30, 2012 | 30.30M |
| June 30, 2012 | 30.57M |
| March 31, 2012 | 31.12M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
140.85M
Minimum
Sep 2019
257.56M
Maximum
Jun 2023
206.89M
Average
222.49M
Median
Research and Development Expense (TTM) Benchmarks
| AIM ImmunoTech Inc | 9.03M |
| Perspective Therapeutics Inc | 28.53M |
| Protalix BioTherapeutics Inc | 12.62M |
| Electromed Inc | 0.656M |
| Armata Pharmaceuticals Inc | 32.40M |